Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Biogen
Deoxyribonucleic acid (DNA) will be analyzed from natalizumab-treated subjects who develop Progressive Multifocal Leukoencephalopathy (PML). The genetic analysis of the subjects will directly seek mutations that could identify subjects at risk.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects who have confirmed PML while on treatment with Natalizumab
